PL2061485T3 - Peptydy EV576 do zastosowania w leczeniu zespołu Guillaina-Barrégo - Google Patents
Peptydy EV576 do zastosowania w leczeniu zespołu Guillaina-BarrégoInfo
- Publication number
- PL2061485T3 PL2061485T3 PL07804199T PL07804199T PL2061485T3 PL 2061485 T3 PL2061485 T3 PL 2061485T3 PL 07804199 T PL07804199 T PL 07804199T PL 07804199 T PL07804199 T PL 07804199T PL 2061485 T3 PL2061485 T3 PL 2061485T3
- Authority
- PL
- Poland
- Prior art keywords
- peptides
- treatment
- barré syndrome
- guillain barré
- guillain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0617734.9A GB0617734D0 (en) | 2006-09-08 | 2006-09-08 | Method of treating peripheral nerve disorders |
PCT/GB2007/003401 WO2008029167A1 (en) | 2006-09-08 | 2007-09-10 | Method of treating peripheral nerve disorders |
EP07804199A EP2061485B1 (en) | 2006-09-08 | 2007-09-10 | EV576 peptides for use in the treatment of Guillain Barré syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2061485T3 true PL2061485T3 (pl) | 2013-03-29 |
Family
ID=37232629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07804199T PL2061485T3 (pl) | 2006-09-08 | 2007-09-10 | Peptydy EV576 do zastosowania w leczeniu zespołu Guillaina-Barrégo |
Country Status (11)
Country | Link |
---|---|
US (4) | US9211312B2 (pl) |
EP (1) | EP2061485B1 (pl) |
JP (1) | JP5557528B2 (pl) |
AU (1) | AU2007293239B2 (pl) |
CA (1) | CA2662715C (pl) |
DK (1) | DK2061485T3 (pl) |
ES (1) | ES2397900T3 (pl) |
GB (1) | GB0617734D0 (pl) |
NZ (1) | NZ575461A (pl) |
PL (1) | PL2061485T3 (pl) |
WO (1) | WO2008029167A1 (pl) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
ES2831325T3 (es) | 2006-10-10 | 2021-06-08 | Regenesance B V | Inhibición del complemento para una mejor regeneración de los nervios |
CN102762223B (zh) | 2010-01-08 | 2014-09-03 | 沃卢申伊谬诺制药公司 | 用于治疗呼吸道病毒性感染的ev576 |
WO2013126006A1 (en) | 2012-02-20 | 2013-08-29 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement c5 |
GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
CA2988313A1 (en) * | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
GB201602802D0 (en) | 2016-02-17 | 2016-03-30 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
KR20240070728A (ko) | 2016-06-14 | 2024-05-21 | 리제너론 파아마슈티컬스, 인크. | 항-c5 항체 및 이의 용도 |
US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
DK3411400T3 (da) | 2017-04-03 | 2021-10-11 | Inflarx Gmbh | Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet |
KR102656199B1 (ko) | 2017-04-21 | 2024-04-09 | 볼루션 이뮤노 파마슈티컬스 에스에이 | 자가면역 수포 질환의 치료를 위한 코버신 |
EP3642230A1 (en) | 2017-06-23 | 2020-04-29 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
WO2019118556A1 (en) | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
WO2020053206A1 (en) | 2018-09-10 | 2020-03-19 | Volution Immuno Pharmaceuticals Sa | Coversin for use in the treatment of rheumatic diseases |
GB201905810D0 (en) | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
JP2023503776A (ja) | 2019-09-27 | 2023-02-01 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 造血幹細胞移植後の血栓性微小血管症(hsct-tma)の治療方法 |
CA3172421A1 (en) | 2020-03-27 | 2021-09-30 | Niels C. Riedemann | Inhibitors of c5a for the treatment of corona virus infection |
GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071096B2 (en) | 2002-01-25 | 2011-12-06 | G2 Therapies Ltd | Anti-C5aR antibodies and uses thereof |
ITMI20021527A1 (it) * | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
ATE427356T1 (de) * | 2003-06-02 | 2009-04-15 | Varleigh Ltd | Komplementinhibitoren aus zecken |
EP1667702A2 (en) * | 2003-09-10 | 2006-06-14 | Baxter International Inc., Baxter Healthcare Corp. | Peptides that inhibit complement activation |
EP1739078A1 (de) * | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
ES2530428T3 (es) | 2006-09-05 | 2015-03-02 | Alexion Pharma Inc | Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos |
GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
-
2006
- 2006-09-08 GB GBGB0617734.9A patent/GB0617734D0/en not_active Ceased
-
2007
- 2007-09-10 US US12/440,462 patent/US9211312B2/en active Active
- 2007-09-10 ES ES07804199T patent/ES2397900T3/es active Active
- 2007-09-10 WO PCT/GB2007/003401 patent/WO2008029167A1/en active Application Filing
- 2007-09-10 DK DK07804199.3T patent/DK2061485T3/da active
- 2007-09-10 CA CA2662715A patent/CA2662715C/en active Active
- 2007-09-10 AU AU2007293239A patent/AU2007293239B2/en active Active
- 2007-09-10 JP JP2009527207A patent/JP5557528B2/ja active Active
- 2007-09-10 EP EP07804199A patent/EP2061485B1/en active Active
- 2007-09-10 NZ NZ575461A patent/NZ575461A/en unknown
- 2007-09-10 PL PL07804199T patent/PL2061485T3/pl unknown
-
2015
- 2015-11-12 US US14/939,154 patent/US20160166641A1/en not_active Abandoned
-
2018
- 2018-05-21 US US15/984,881 patent/US20190117730A1/en not_active Abandoned
-
2021
- 2021-09-22 US US17/481,528 patent/US20220249608A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2662715C (en) | 2018-04-03 |
US20160166641A1 (en) | 2016-06-16 |
JP5557528B2 (ja) | 2014-07-23 |
EP2061485A1 (en) | 2009-05-27 |
US20190117730A1 (en) | 2019-04-25 |
GB0617734D0 (en) | 2006-10-18 |
JP2010502686A (ja) | 2010-01-28 |
AU2007293239B2 (en) | 2012-07-05 |
AU2007293239A1 (en) | 2008-03-13 |
CA2662715A1 (en) | 2008-03-13 |
US9211312B2 (en) | 2015-12-15 |
US20100111929A1 (en) | 2010-05-06 |
DK2061485T3 (da) | 2012-11-19 |
ES2397900T3 (es) | 2013-03-12 |
US20220249608A1 (en) | 2022-08-11 |
EP2061485B1 (en) | 2012-08-22 |
NZ575461A (en) | 2011-11-25 |
WO2008029167A1 (en) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2061485T3 (pl) | Peptydy EV576 do zastosowania w leczeniu zespołu Guillaina-Barrégo | |
LT2068889T (lt) | Anakinra, naudojama bronchiolito obliteranso sindromo gydymui | |
HK1252316A1 (zh) | IL-1β抗體的用途 | |
IL243534A0 (en) | Methods for the preparation of biologically active compounds in the form of nanoparticles | |
ZA200800464B (en) | Peptides for use in the treatment of obesity | |
EP2054521A4 (en) | METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES | |
EP2032156A4 (en) | COMPOSITIONS AND METHOD FOR THE DELIVERY OF OXYGEN | |
PT2152290E (pt) | Métodos para administrar anticorpos anti-il-5 | |
PL2049142T5 (pl) | Preparaty kaspofunginy | |
ZA200808409B (en) | Use of rasagiline for the treatment of restless legs syndrome | |
IL194202A0 (en) | Treatment using citrulline | |
IL192373A (en) | Arginine cyclic peptides and their use in the treatment of fungal infections | |
SI2054088T1 (sl) | Naprava za obdelavo vsebnikov | |
HUE037109T2 (hu) | Endoxifén rák kezelésében történõ alkalmazásra | |
GB0722996D0 (en) | Depsipeptides and their therapeutic use | |
GB2443933B (en) | Vapour delivering device | |
GB0609121D0 (en) | Peptide Therapy | |
ZA200806949B (en) | Medicinal formulation for the treatment for hepatitis C | |
EP2005964A4 (en) | MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF | |
GB0403808D0 (en) | Films for use as dosage forms | |
HK1138189A1 (en) | Use of a compound in the manufacture of a medicament for the treatment of leukaemia | |
TWI370735B (en) | Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome | |
GB0625671D0 (en) | Protein formulation | |
HK1125634A1 (en) | Pharmaceutical for use in the treatment of ureterolithiasis | |
GB0613920D0 (en) | Tha angle footstool |